ABT - Abbott Laboratories

$89.3+0.98%

Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes

Abbott ) announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes. The test will run on the company's ID NOW™ platform, providing rapid results in a wide range of healthcare settings such as physicians' offices, urgent care clinics and hospital emergency departments.

Testing being performed on Abbott’s ID NOW platform

ID NOW test components being made in Abbott’s U.S. manufacturing facility

The ID NOW platform is small, lightweight (6.6 pounds) and portable (the size of a small toaster), and uses molecular technology, which is valued-of-care testing platform in the U.S. today.

"The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said Robert B. Ford, president and chief operating officer, Abbott. "With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots."

Abbott will be making ID NOW COVID-19 tests available next week to healthcare providers in urgent care settings in the U.S., where the majority of ID NOW instruments are in use today. The company is working with the Administration to deploy tests to areas where they can have the greatest impact.

The arrival of the Abbott ID NOW COVID-19 test comes a week after the company launched its Abbott _m_2000™ RealTi_m_e SARS-CoV-2 EUA test, which runs on the _m_2000™ RealTi_m_e System located in hospital and reference labs around the world. Between the two platforms, Abbott expects to produce about 5 million tests per month.

About the ID NOW™ Molecular Platform
As the world leader in point-of-care diagnostics, Abbott is adding its expertise and scale to help fight the COVID-19 global pandemic. First introduced in 2014, ID NOW is the leading molecular point-of-care platform for Influenza A & B, Strep A and RSV testing in the U.S.

ID NOW is a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. Its unique isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing clinicians to make evidence-based clinical decisions during a patient visit.

👋 Welcome to our community for investors. Join for free to personalize your experience and participate on discussions.

Disclaimer: FinSharing does not guarantee that any of the information available on our website, APIs or provided by any other means is complete, accurate, current, reliable or appropriate for your needs. Some of our information is provided by third party services and we cannot guarantee that is complete, accurate, current, reliable or appropriate for your needs. The information and recommendations on this site are for educational purposes only and should not be used to replace the advice of financial advisors and other professionals. All our services, information, data and/or recommendations are provided on an "as is" basis and without warranties of any kind, either express or implied. We do not guarantee that our services, information, data and/or recommendations are complete, accurate, current, reliable or appropriate for your needs. Read more